IMMUNITYBIO, INC. (IBRX) Dividend Safety
- Dividend payout ratio · 12 months: Value (m); Formula and calculation Cash dividends paid / net income. Period ending 2026-06-30..
Dividend safety
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Dividend payout ratio · 12 months | (m) | Cash dividends paid / net income. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Dividend payments · 12 months | (m) | |
| Net income · 12 months | -992.46M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Dividend payments · 12 months (USD) | Net income · 12 months (USD) | Dividend payout |
|---|---|---|---|
| 2026-06-30 | (m) | $-992.46M | (m) |
| 2026-03-31 | (m) | $-854.64M | (m) |
| 2025-12-31 | (m) | $-351.40M | (m) |
| 2025-09-30 | (m) | $-348.62M | (m) |
| 2025-06-30 | (m) | $-367.09M | (m) |
| 2025-03-31 | (m) | $-409.10M | (m) |
| 2024-12-31 | (m) | $-413.56M | (m) |
| 2024-09-30 | (m) | $-587.79M | (m) |
| 2024-06-30 | (m) | $-597.65M | (m) |
| 2024-03-31 | (m) | $-600.96M | (m) |
| 2023-12-31 | (m) | $-583.20M | (m) |
| 2023-09-30 | (m) | $-458.02M | (m) |
| 2023-06-30 | (m) | $-473.38M | (m) |
| 2023-03-31 | (m) | $-430.08M | (m) |
| 2022-12-31 | (m) | $-416.57M | (m) |
| 2022-09-30 | (m) | $-399.61M | (m) |
| 2022-06-30 | (m) | $-376.30M | (m) |
| 2022-03-31 | (m) | $-370.00M | (m) |
| 2021-12-31 | (m) | $-346.79M | (m) |
| 2021-09-30 | (m) | $-325.64M | (m) |
| 2021-06-30 | (m) | $-303.61M | (m) |
| 2021-03-31 | (m) | $-266.76M | (m) |
| 2020-12-31 | (m) | $-92.38M | (m) |
| 2020-09-30 | (m) | $-75.89M | (m) |
| 2020-06-30 | (m) | $-69.70M | (m) |
| 2020-03-31 | (m) | $-66.29M | (m) |
| 2019-12-31 | (m) | $-65.79M | (m) |
| 2019-09-30 | (m) | $-67.49M | (m) |
| 2019-06-30 | (m) | $-75.54M | (m) |
| 2019-03-31 | (m) | $-86.59M | (m) |
| 2018-12-31 | (m) | $-96.23M | (m) |
| 2018-09-30 | (m) | $-103.37M | (m) |
| 2018-06-30 | (m) | $-103.71M | (m) |
| 2018-03-31 | (m) | $-99.43M | (m) |
| 2017-12-31 | (m) | $-96.42M | (m) |
| 2017-09-30 | (m) | $-96.17M | (m) |
| 2017-06-30 | (m) | $-104.10M | (m) |
| 2017-03-31 | (m) | $-114.65M | (m) |
| 2016-12-31 | (m) | $-120.81M | (m) |
| 2016-09-30 | (m) | $-123.39M | (m) |
| 2016-06-30 | (m) | $-137.81M | (m) |
| 2016-03-31 | (m) | $-234.68M | (m) |
| 2015-12-31 | (m) | $-236.88M | (m) |
| 2015-09-30 | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) |
| 2015-03-31 | (m) | $-37.95M | (m) |
| 2014-12-31 | (m) | $-6.18M | (m) |
| 2014-09-30 | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) |
| 2013-12-31 | (m) | $-2.05M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |